Table 1.

Issues relating to the therapy of chronic myeloid leukemia (CML) in early chronic phase that are still unresolved in 2009.

  1. How important is it to aim for a major molecular response (MMR) in a person who has achieved a complete cytogenetic response (CCyR)?

  2. Are imatinib plasma levels useful for adjusting imatinib dosage in the clinic?

  3. How should we approach the question of compliance/adherence in a person who has been taking imatinib for, say, one year?

  4. Should some patients who fail imatinib at 400 mg/daily be offered 600 mg or 800 mg/daily, or go directly to a second-generation tyrosine kinase inhibitor (TKI)?

  5. To what extent should the finding of KD domain mutations (other than T315I) dictate choice of subsequent therapy?

  6. What patients are clearly candidates for allogeneic stem cell transplantation (SCT)?

  7. When can we safely stop imatinib in a responding patient (if at all)?

  8. How can we best treat a woman who wants to a child?

  9. Are we ready to give a second generation as primary treatment to chronic-phase CML (CML-CP) outside the context of a clinical trial?

 

  1. How important is it to aim for a major molecular response (MMR) in a person who has achieved a complete cytogenetic response (CCyR)?

  2. Are imatinib plasma levels useful for adjusting imatinib dosage in the clinic?

  3. How should we approach the question of compliance/adherence in a person who has been taking imatinib for, say, one year?

  4. Should some patients who fail imatinib at 400 mg/daily be offered 600 mg or 800 mg/daily, or go directly to a second-generation tyrosine kinase inhibitor (TKI)?

  5. To what extent should the finding of KD domain mutations (other than T315I) dictate choice of subsequent therapy?

  6. What patients are clearly candidates for allogeneic stem cell transplantation (SCT)?

  7. When can we safely stop imatinib in a responding patient (if at all)?

  8. How can we best treat a woman who wants to a child?

  9. Are we ready to give a second generation as primary treatment to chronic-phase CML (CML-CP) outside the context of a clinical trial?

 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal